NCT00991458

Study of Cyclosporine in Post-LASIK Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 621 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 21 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.

Conditions

• Laser In Situ Keratomileusis

Interventions

Type	Name	Description
DRUG	Cyclosporine 0.010% eye drops	Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
DRUG	Cyclosporine 0.005% eye drops	Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
DRUG	Placebo (Vehicle for Cyclosporine)	Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2009-10-08
• Last updated: 2013-07-11
• Results posted: 2013-07-11

Locations

1 site across 1 country: United States